Table 3.

Neutralising antibody responses to live SARS-CoV-2 28 days after each dose in the phase 1 trial

	Day 28 after first dose			Day 28 after second dose
	3 μg group	6 μg group	p value	3 μg group	6 μg group	p value
Seroconversion rate
Total	13/24 (54·2% [32·8–74·5])	15/24 (62·5% [40·6–81·2])	0·558	24/24 (100·0% [85·8–100·0])	22/23 (95·7% [78·1–99·9])	0·489
60–64 years	8/12 (66·7% [34·9–90·1])	5/9 (55·6% [21·2–86·3])	0·673	12/12 (100·0% [73·5–100·0])	8/9 (88·9% [51·8–99·7])	0·429
65–69 years	3/6 (50·0% [11·8–88·2])	5/8 (62·5% [24·5–91·5])	1·000	6/6 (100·0% [54·1–100·0])	7/7 (100·0% [59·0–100·0])	1·000
≥70 years	2/6 (33·3% [4·3–77·7])	5/7 (71·4% [29·0–96·3])	0·286	6/6 (100·0% [54·1–100·0])	7/7 (100·0% [59·0–100·0])	1·000
Geometric mean titre
Total	6·9 (4·6–10·2)	9·1 (6·4–13·0)	0·278	54·9 (38·6–78·2)	64·4 (41·5–99·7)	0·560
60–64 years	10·0 (5·7–17·8)	9·7 (4·9–19·4)	0·934	69·5 (38·9–124·2)	43·9 (15·9–120·7)	0·355
65–69 years	5·5 (2·3–13·1)	7·4 (3·2–17·4)	0·562	56·5 (35·7–89·6)	76·5 (32·5–178·4)	0·485
≥70 years	4·0 (1·6–10·0)	10·5 (6·0–18·4)	0·039	33·3 (13·4–82·8)	89·1 (57·6–137·8)	0·025

Seroconversion rates are n/N (% [95% CI]). Geometric mean titres are shown with 95% CIs.